 Theresa Pacheco
Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 10 | 2022 | 762 | 1.070 |
Why?
| | Immunocompromised Host | 2 | 2019 | 200 | 0.810 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 4 | 2022 | 41 | 0.750 |
Why?
| | Carcinoma | 1 | 2019 | 204 | 0.610 |
Why?
| | Tumor Suppressor Proteins | 2 | 2015 | 289 | 0.610 |
Why?
| | Lentigo | 1 | 2015 | 5 | 0.540 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2010 | 43 | 0.380 |
Why?
| | Mycosis Fungoides | 2 | 2022 | 62 | 0.370 |
Why?
| | Tetracycline | 2 | 2000 | 13 | 0.360 |
Why?
| | Cafe-au-Lait Spots | 1 | 2007 | 3 | 0.310 |
Why?
| | Intestinal Polyps | 1 | 2007 | 16 | 0.300 |
Why?
| | Incontinentia Pigmenti | 1 | 2006 | 3 | 0.290 |
Why?
| | LEOPARD Syndrome | 1 | 2004 | 2 | 0.250 |
Why?
| | Noonan Syndrome | 1 | 2004 | 17 | 0.240 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 56 | 0.240 |
Why?
| | Plasmacytoma | 1 | 2003 | 11 | 0.240 |
Why?
| | Melanoma | 4 | 2007 | 664 | 0.220 |
Why?
| | Photochemotherapy | 1 | 2022 | 29 | 0.220 |
Why?
| | Lupus Erythematosus, Discoid | 1 | 2002 | 7 | 0.210 |
Why?
| | Lupus Erythematosus, Cutaneous | 1 | 2000 | 6 | 0.190 |
Why?
| | Angioedema | 1 | 2000 | 17 | 0.190 |
Why?
| | Trans-Activators | 2 | 2000 | 373 | 0.180 |
Why?
| | Parvovirus | 1 | 1999 | 13 | 0.170 |
Why?
| | Hydroxamic Acids | 2 | 2009 | 80 | 0.160 |
Why?
| | Heart Transplantation | 1 | 2003 | 671 | 0.150 |
Why?
| | Lung Transplantation | 1 | 2019 | 263 | 0.150 |
Why?
| | Cell Cycle Proteins | 1 | 2000 | 565 | 0.140 |
Why?
| | Carrier Proteins | 1 | 2000 | 726 | 0.130 |
Why?
| | Hyperthermia, Induced | 2 | 2007 | 67 | 0.130 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 1384 | 0.130 |
Why?
| | Genetic Linkage | 1 | 2015 | 321 | 0.120 |
Why?
| | Mosaicism | 2 | 2006 | 62 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 1999 | 1167 | 0.120 |
Why?
| | Humans | 19 | 2022 | 118972 | 0.110 |
Why?
| | Male | 12 | 2022 | 57801 | 0.110 |
Why?
| | Facial Neoplasms | 1 | 2011 | 18 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1022 | 0.090 |
Why?
| | Lymphoma, B-Cell | 1 | 2010 | 85 | 0.090 |
Why?
| | Doxycycline | 2 | 2000 | 60 | 0.090 |
Why?
| | Adenoma | 1 | 2011 | 191 | 0.090 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2009 | 200 | 0.080 |
Why?
| | Tumor Cells, Cultured | 2 | 2000 | 874 | 0.080 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2007 | 31 | 0.070 |
Why?
| | Transfection | 2 | 2000 | 888 | 0.070 |
Why?
| | Phenotype | 1 | 2015 | 3003 | 0.070 |
Why?
| | Tooth Abnormalities | 1 | 2006 | 11 | 0.070 |
Why?
| | Salvage Therapy | 1 | 2007 | 130 | 0.070 |
Why?
| | Karyotyping | 1 | 2006 | 102 | 0.070 |
Why?
| | Middle Aged | 7 | 2022 | 27617 | 0.070 |
Why?
| | Nervous System Malformations | 1 | 2006 | 33 | 0.070 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 241 | 0.070 |
Why?
| | Lod Score | 1 | 2004 | 75 | 0.060 |
Why?
| | Nevus, Pigmented | 1 | 2004 | 33 | 0.060 |
Why?
| | Eosinophils | 1 | 2006 | 282 | 0.060 |
Why?
| | Female | 9 | 2022 | 61564 | 0.060 |
Why?
| | Equipment Failure Analysis | 1 | 2004 | 139 | 0.060 |
Why?
| | Aged | 3 | 2019 | 19657 | 0.060 |
Why?
| | Eczema | 1 | 2004 | 85 | 0.060 |
Why?
| | Forearm | 1 | 2003 | 117 | 0.060 |
Why?
| | Specimen Handling | 1 | 2004 | 165 | 0.060 |
Why?
| | Perylene | 1 | 2022 | 7 | 0.060 |
Why?
| | Ointments | 1 | 2022 | 25 | 0.050 |
Why?
| | Anthracenes | 1 | 2022 | 30 | 0.050 |
Why?
| | Mutation | 2 | 2006 | 3457 | 0.050 |
Why?
| | Adult | 5 | 2022 | 31512 | 0.050 |
Why?
| | Photosensitizing Agents | 1 | 2022 | 28 | 0.050 |
Why?
| | Hot Temperature | 1 | 2004 | 334 | 0.050 |
Why?
| | Cell Culture Techniques | 1 | 2004 | 356 | 0.050 |
Why?
| | Skin | 1 | 2006 | 657 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2002 | 59 | 0.050 |
Why?
| | Thymidine Kinase | 1 | 2000 | 14 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2000 | 14 | 0.050 |
Why?
| | Lower Extremity | 1 | 2003 | 335 | 0.050 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 52 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2000 | 58 | 0.050 |
Why?
| | Colorado | 2 | 2007 | 4196 | 0.050 |
Why?
| | Luciferases | 1 | 2000 | 143 | 0.040 |
Why?
| | Simplexvirus | 1 | 2000 | 86 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 126 | 0.040 |
Why?
| | Diseases in Twins | 1 | 2000 | 181 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1691 | 0.040 |
Why?
| | Pedigree | 1 | 2000 | 485 | 0.040 |
Why?
| | Plasmids | 1 | 2000 | 355 | 0.040 |
Why?
| | Transduction, Genetic | 1 | 1999 | 116 | 0.040 |
Why?
| | Clone Cells | 1 | 1999 | 248 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1974 | 0.040 |
Why?
| | Genes, Reporter | 1 | 1999 | 270 | 0.040 |
Why?
| | Apoptosis | 1 | 2007 | 2484 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2002 | 521 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2018 | 287 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 1999 | 348 | 0.040 |
Why?
| | Cell Cycle | 1 | 2000 | 550 | 0.040 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 653 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2000 | 1085 | 0.040 |
Why?
| | Child, Preschool | 2 | 2007 | 9491 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2022 | 9342 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2006 | 5255 | 0.030 |
Why?
| | Mohs Surgery | 1 | 2011 | 25 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2445 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2007 | 2851 | 0.020 |
Why?
| | Adolescent | 1 | 2007 | 18480 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1166 | 0.020 |
Why?
| | Child | 1 | 2007 | 19129 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2007 | 129 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2007 | 185 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2007 | 324 | 0.020 |
Why?
| | Caspases | 1 | 2007 | 269 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2007 | 174 | 0.020 |
Why?
| | Probability | 1 | 2007 | 305 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 736 | 0.020 |
Why?
| | Administration, Oral | 1 | 2007 | 756 | 0.020 |
Why?
| | Survival Analysis | 1 | 2007 | 1267 | 0.010 |
Why?
| | Feedback | 1 | 2004 | 153 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1223 | 0.010 |
Why?
| | Medical Records | 1 | 2004 | 163 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 1945 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2007 | 671 | 0.010 |
Why?
| | Equipment Design | 1 | 2004 | 519 | 0.010 |
Why?
| | Child Welfare | 1 | 2004 | 199 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 622 | 0.010 |
Why?
| | Cell Survival | 1 | 2004 | 1047 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 4596 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2275 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2004 | 3171 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2007 | 6561 | 0.010 |
Why?
| | Risk Factors | 1 | 2004 | 9000 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2004 | 12978 | 0.000 |
Why?
|
|
Pacheco's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|